Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines.

Details

Serval ID
serval:BIB_03AC0A9816BB
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines.
Journal
Human vaccines & immunotherapeutics
Author(s)
Jamshidi E., Asgary A., Shafiekhani P., Khajeamiri Y., Mohamed K., Esmaily H., Jamal Rahi S., Mansouri N.
ISSN
2164-554X (Electronic)
ISSN-L
2164-5515
Publication state
Published
Issued date
30/11/2022
Peer-reviewed
Oui
Volume
18
Number
5
Pages
2037384
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccine's antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively.
Keywords
2019-nCoV Vaccine mRNA-1273, Ad26COVS1, Antibodies, Neutralizing, Antibodies, Viral, BNT162 Vaccine, COVID-19/prevention & control, COVID-19 Vaccines, ChAdOx1 nCoV-19, Humans, Vaccination, Antibody persistence, COVID-19, Cell-mediated immunity, Humoral immunity, Immunogenicity, Long-term immunity, Long-term protection, SARS-CoV-2, Vaccines
Pubmed
Web of science
Open Access
Yes
Create date
19/04/2022 13:47
Last modification date
20/07/2022 6:39
Usage data